Press Release

Mitsubishi Tanabe Pharma Corporation

Launch of Anti-allergy Agent, Bepotastine Besilate in China and Indonesia

Osaka, Japan, May 27, 2011---Mitsubishi Tanabe Pharma Corporation (President: & CEO: Michihiro Tsuchiya) announced today that it has launched anti-allergy agent, bepotastine besilate (product name in Japan: Talion®) in China and Indonesia through its consolidated subsidiaries, Tianjin Tanabe Seiyaku Co., Ltd. (Head Office: Tianjin, China) and P.T. Tanabe Indonesia (Head Office: Jakarta, Indonesia), respectively.

Bepotastine besilate was originated by Ube Industries, Ltd. (Head Office: Ube, Yamaguchi, President: Michio Takeshita) and jointly developed by Ube Industries and Mitsubishi Tanabe Pharma. Since 2000, it has been marketed in Japan by Mitsubishi Tanabe Pharma as a treatment for allergic diseases under the brand name of Talion® tablets.

Since 2004, it has also been sold in South Korea by Dong-A Pharmaceutical Co., Ltd. (Head Office: Seoul, South Korea) under a license agreement with Mitsubishi Tanabe Pharma.

Mitsubishi Tanabe Pharma will strive to contribute to the treatment of allergic diseases in China and Indonesia through the launch of bepotastine besilate.

< For inquiries, contact >
Corporate Communications Department
Tel: +81-6-6205-5211